MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

Search

ANI Pharmaceuticals Inc

Cerrado

SectorSanidad

79.08 -2.68

Resumen

Variación precio

24h

Actual

Mínimo

79

Máximo

80.95

Métricas clave

By Trading Economics

Ingresos

18M

27M

Ventas

16M

228M

P/B

Media del Sector

51.744

78.892

BPA

2.04

Margen de beneficios

11.684

Empleados

897

EBITDA

19M

61M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+33.18% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-284M

1.8B

Apertura anterior

81.76

Cierre anterior

79.08

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

ANI Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 dic 2025, 22:03 UTC

Principales Movimientos del Mercado

Mining Stocks Slip Near the End of Stellar Year

29 dic 2025, 15:57 UTC

Principales Movimientos del Mercado

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 dic 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Decline; Yen in Focus -- Market Talk

29 dic 2025, 23:38 UTC

Adquisiciones, fusiones, absorciones

Manus: Will Continue to Operate From Singapore

29 dic 2025, 23:38 UTC

Adquisiciones, fusiones, absorciones

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 dic 2025, 23:37 UTC

Adquisiciones, fusiones, absorciones

Meta Platforms: Will Integrate Manus Service Into Products

29 dic 2025, 23:36 UTC

Adquisiciones, fusiones, absorciones

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 dic 2025, 23:36 UTC

Adquisiciones, fusiones, absorciones

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 dic 2025, 23:35 UTC

Adquisiciones, fusiones, absorciones

Manus to Join Meta Platforms

29 dic 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

Origin: Raise Values Kraken at US$8.65 Billion

29 dic 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 dic 2025, 21:31 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 dic 2025, 21:31 UTC

Adquisiciones, fusiones, absorciones

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 dic 2025, 21:30 UTC

Adquisiciones, fusiones, absorciones

Origin's Kraken Stake to Remain at 22.7%

29 dic 2025, 21:30 UTC

Adquisiciones, fusiones, absorciones

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 dic 2025, 21:30 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 dic 2025, 21:30 UTC

Adquisiciones, fusiones, absorciones

Origin: Additional Interest Offsets Dilution From Raise

29 dic 2025, 21:30 UTC

Adquisiciones, fusiones, absorciones

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 dic 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 dic 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 dic 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 dic 2025, 21:27 UTC

Adquisiciones, fusiones, absorciones

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 dic 2025, 20:22 UTC

Charlas de Mercado

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 dic 2025, 20:14 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 dic 2025, 20:02 UTC

Adquisiciones, fusiones, absorciones

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 dic 2025, 17:36 UTC

Charlas de Mercado

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Comparación entre iguales

Cambio de precio

ANI Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

33.18% repunte

Estimación a 12 Meses

Media 109.75 USD  33.18%

Máximo 121 USD

Mínimo 100 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ANI Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

4

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

70.05 / 71.85Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

149 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.